NETSPOT
Peak68ga-dotatate
NDAINTRAVENOUSPOWDERPriority Review
Approved
Jun 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
68 dotatate binds to somatostatin receptors, with highest affinity for subtype 2 receptors (SSTR2). It binds to cells that express somatostatin receptors, including malignant cells, which overexpress SSTR2. Gallium-68 is a β+ emitting radionuclide with an emission yield that allows PET imaging.
Clinical Trials (1)
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
Started Mar 2013
169 enrolled
Neuroendocrine Carcinoma
Loss of Exclusivity
LOE Date
Aug 10, 2032
78 months away
Patent Expiry
Aug 10, 2032
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 9375498 | Aug 10, 2032 | Product | — |
External Resources